

1FW

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/642,549	
	Filing Date		
	First Named Inventor	RICHARD F. DECHANT	
	Art Unit	1614	
	Examiner Name	MICHELLE GRAFFEO	
Total Number of Pages in This Submission	11	Attorney Docket Number	08/18/2003

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input checked="" type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): REPLY TO OFFICE ACTION MEMO
<div>Remarks</div>		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	RICHARD F. DECHANT	
Signature	<i>Richard F. Dechant</i>	
Date	02/10/06	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: _____			
Typed or printed			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



May 13, 2004

Dr T.M. Baker
The Permanente Medical Group
2345 Fair Oaks Blvd
Sacramento, CA 95825

Dear Dr. Baker,


In a belated response to your letter of April 16, I would like to thank you for your concern.

At the present time there is no indication of a tumor on my scalp, and I do not wish to have an operation. You have made it clear that you have placed no credence in what I had to say about the tumor, about my composition for cancer treatment, and about my treatise concerning cancer.

I do want repeat what occurred three days after you took the biopsy specimen. A swelling in my scalp adjacent to my left ear occurred which was not painful until touched. My inner ear also became painful. What had occurred may not have been a metastasis but was equivalent to one, since virulent cancer cell(s) were released into my bloodstream. Had it not been for my composition that I mentioned to you, I would now be having chemotherapy and radiation treatment. As it turned out the pain subsided after two applications of my composition.

Sincerely,
Richard DeCharet

MSDS Number: **R3900** * * * * * Effective Date: **02/18/03** * * * * * Supersedes: **04/04/00**



MSDS Material Safety Data Sheet

From: Mallinckrodt Baker, Inc.
222 Red School Lane
Phillipsburg, NJ 08865



Mallinckrodt
CHEMICALS



24 Hour Emergency Telephone: 800-852-2537
CHEMTREC: 1-800-424-6300

National Response in Canada
CANUTEC: 613-896-6666

Outside U.S. and Canada
Chemtrec: 703-527-3887

NOTE: CHEMTREC, CANUTEC and National Response Center emergency numbers to be used only in the event of chemical emergencies involving a spill, leak, fire, exposure or accident involving chemicals.

All non-emergency questions should be directed to Customer Service (1-800-582-2537) for assistance

RESORCINOL

I. Product Identification

Synonyms: Resorcin; 1-3 Dihydroxybenzene; m-Benzenediol; 1,3-Benzenediol
CAS No.: 108-46-3
Molecular Weight: 110.11
Chemical Formula: C₆H₆O₂
Product Codes:
J.T. Baker: 3360, 3366, 3368
Mallinckrodt: 7232

. Composition/Information on Ingredients

Ingredient	CAS No	Percent	Hazardous
Resorcinol	108-46-3	90 - 100%	Yes

. Hazards Identification

Emergency Overview

DANGER! MAY BE FATAL IF SWALLOWED. HARMFUL IF INHALED OR ABSORBED THROUGH SKIN. MAY CAUSE METHEMOGLOBINEMIA. AFFECTS CARDIOVASCULAR SYSTEM, CENTRAL NERVOUS SYSTEM, BLOOD, SPLEEN, LIVER AND KIDNEYS. CAUSES SEVERE IRRITATION TO SKIN AND EYES. CAUSES IRRITATION TO RESPIRATORY TRACT. MAY CAUSE ALLERGIC SKIN REACTION.

J.T. Baker SAF-T-DATA^(tm) Ratings (Provided here for your convenience)

Health Rating: 2 - Moderate

Flammability Rating: 1 - Slight

Reactivity Rating: 1 - Slight

Contact Rating: 2 - Moderate

Lab Protective Equip: GOGGLES; LAB COAT; VENT HOOD; PROPER GLOVES

Storage Color Code: Orange (General Storage)

Potential Health Effects

Inhalation:

Inhalation of dust causes irritation to respiratory tract. Toxic effects may follow and include methemoglobinemia, convulsions, and death.

Ingestion:

Toxic! A poison to blood and nerves. Causes gastrointestinal upset with severe diarrhea, sweating, weakness, headache, dizziness, cyanosis, spleen damage, kidney damage, cardiovascular effects, liver damage, and possibly convulsions and death.

Skin Contact:

Strong irritant to skin, causing severe dermatitis and loss of superficial layers of skin. Can be absorbed through skin with severe exposures producing symptoms paralleling ingestion and enlargement of local lymph glands. May cause allergic skin reactions.

Eye Contact:

Strong irritant. Can cause permanent damage.

Chronic Exposure:

Target organs include liver and kidneys.

Aggravation of Pre-existing Conditions:

Persons with pre-existing disorders of the blood, skin, liver, kidneys or lungs may be at an increased risk from exposure.

4. First Aid Measures

Inhalation:

Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention immediately.

Ingestion:

If swallowed, give large quantities of water to drink and get medical attention immediately. Never give anything by mouth to an unconscious person.

Skin Contact:

Immediately flush skin with plenty of soap and water for at least 15 minutes while removing

10/642,549

The Permanente Medical Group, Inc.

2345 FAIR OAKS BOULEVARD
SACRAMENTO, CALIFORNIA 95625
(916) 973-5000



ANTIOCH
CAMPBELL
DAVIS
FAIRFIELD
FREMONT
FRESNO
GILROY
HAYWARD
MARTINEZ
MILPITAS
MOUNTAIN VIEW
NAPA
NOVATO
OAKLAND
PARK SHADELANDS
PETALUMA
PLEASANTON

RANCHO CORDOVA
REDWOOD CITY
RICHMOND
ROSEVILLE
SACRAMENTO
SAN FRANCISCO
SAN JOSE
SAN RAFAEL
SANTA CLARA
SANTA ROSA
S. SACRAMENTO
S. SAN FRANCISCO
STOCKTON
VACAVILLE
VALLEJO
WALNUT CREEK

April 16, 2004

Mr Richard Dechant
500 Dunbarton Circle
Sacramento, CA 95825

Dear Mr. Dechant:

I am writing this letter regarding our discussion in clinic on April 12, 2004. As we discussed, your scalp biopsy demonstrated a sclerosing or morpheaform basal cell carcinoma, which has a tendency to aggressively infiltrate the surrounding tissue. Although this type of cancer does not typically metastasize, it can be quite destructive locally. If left in place, it does have the ability to invade the adjacent structures, such as muscle and skull, and, given enough time, it could lead to significant health problems and even death. I respect your right to decide against any surgical treatment, but I urge you to reconsider. The surgery would only involve an approximately 45-60 minute procedure performed under a local anesthetic and would require no time in the hospital. If you change your mind regarding this issue, please contact us to arrange for surgery at (916) 631-3010. Regardless of your decision, I would like to see you back in approximately 6 months for a routine skin examination to check for any new skin cancers.

Sincerely,

Timothy M. Baker, MD



KAISER PERMANENTE®